scholarly journals Associations between prenatal serum levels of leptin, IGF-I, and estradiol and adolescent mothers’ height gain during and after pregnancy

PLoS ONE ◽  
2020 ◽  
Vol 15 (2) ◽  
pp. e0228706
Author(s):  
Reyna Sámano ◽  
Hugo Martínez-Rojano ◽  
Gabriela Chico-Barba ◽  
María Hernández-Trejo ◽  
Raymundo Guzmán ◽  
...  
Keyword(s):  
Adolescent Mothers ◽  
Serum Levels ◽  
Igf I ◽  
Height Gain

Efficacy of long-term growth hormone therapy in short non-growth hormone-deficient children

2017 ◽  
Vol 30 (2) ◽  
Author(s):  
Lucia Schena ◽  
Cristina Meazza ◽  
Sara Pagani ◽  
Valeria Paganelli ◽  
Elena Bozzola ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Final Height ◽  
Standard Deviation Score ◽  
Bone Age ◽  
Gh Treatment ◽  
Short Children ◽  
Igf I ◽  
Height Gain ◽  
The Cost

AbstractBackground:In recent years, several studies have been published showing different responses to growth hormone (GH) treatment in idiopathic short stature children. The aim of the present study was to investigate whether non-growth-hormone-deficient (non-GHD) short children could benefit from long-term GH treatment as GHD patients.Methods:We enrolled 22 prepubertal children and 22 age- and sex-matched GHD patients, with comparable height, body mass index (BMI), bone age, and insulin-like growth factor 1 (IGF-I) circulating levels. The patients were treated with recombinant human GH (rhGH) and followed until they reach adult height.Results:During GH treatment, the two groups grew in parallel, reaching the same final height-standard deviation score (SDS) and the same height gain. On the contrary, we found significantly lower IGF-I serum concentrations in non-GHD patients than in GHD ones, at the end of therapy (p=0.0055).Conclusions:In our study, the response to GH treatment in short non-GHD patients proved to be similar to that in GHD ones. However, a careful selection of short non-GHD children to be treated with GH would better justify the cost of long-term GH therapy.

Immunoreactive IGF-II in serum of healthy subjects and patients with growth hormone disturbances and uraemia

1984 ◽  
Vol 107 (2) ◽  
pp. 164-170 ◽  
Author(s):  
Gösta Enberg ◽  
Kerstin Hall
Keyword(s):  
Confidence Limit ◽  
Binding Protein ◽  
Protein S ◽  
Serum Levels ◽  
Cross Reaction ◽  
Diabetic Patients ◽  
Serum Samples ◽  
Igf I ◽  
Age Dependent ◽  
The Mean

Abstract. A radioimmunoassay has been developed for IGF-II, using Sepharose-coupled antibodies. Porcine insulin, human insulin and human proinsulin showed no cross-reaction, whereas the cross-reaction for IGF-I was 10%. To minimize the influence of the binding protein(s), all serum samples were extracted with acid ethanol before assay. The mean serum level of immunoreactive IGF-II and 95% confidence limit in 46 healthy adults were 587 ng/ml and 354–974 ng/ml, respectively. In contrast to the declining levels of IGF-I with increasing age, no such age-dependent decrease was found for IGF-II levels between 20 to 70 years. No difference in IGF-II levels was found between patients with acromegaly and healthy adult controls. In cord serum and serum from adult patients with GH deficiency the levels were significantly lower (P < 0.001) compared to controls. In diabetic patients with uraemia the mean level and 95% confidence limit were 1222 ng/ml and 532–2808 ng/ml, respectively. Thus, significantly increased serum levels of immunoreactive IGF-II have only been found in serum from patients with uraemia. Whether this is due to an increased production of IGF-II, or secondary to other factors such as the binding protein(s), will require further investigation.

scholarly journals The Relationship between Dioxin-Like Polychlorobiphenyls and IGF-I Serum Levels in Healthy Adults: Evidence from a Cross-Sectional Study

PLoS ONE ◽  
2012 ◽  
Vol 7 (5) ◽  
pp. e38213 ◽  
Author(s):  
Octavio P. Luzardo ◽  
Luis Alberto Henríquez-Hernández ◽  
Pilar F. Valerón ◽  
Pedro C. Lara ◽  
Maira Almeida-González ◽  
...  
Keyword(s):  
Serum Levels ◽  
Cross Sectional Study ◽  
Healthy Adults ◽  
Sectional Study ◽  
Cross Sectional ◽  
Igf I ◽  
The Relationship

Divergence between hepatic insulin-like growth factor (IGF)-I mRNA expression and IGF-I serum levels in Leishmania (Leishmania) infantum chagasi-infected dogs

2013 ◽  
Vol 151 (1-2) ◽  
pp. 163-167
Author(s):  
Flaviane A. Pinho ◽  
Nilton A. Magalhães ◽  
Kleverton R. Silva ◽  
Aline A. Carvalho ◽  
Fernando L.L. Oliveira ◽  
...  
Keyword(s):  
Growth Factor ◽  
Mrna Expression ◽  
Leishmania Infantum ◽  
Serum Levels ◽  
Insulin Like Growth Factor ◽  
Igf I ◽  
Leishmania Infantum Chagasi

scholarly journals Early but not late administration of glucagon-like peptide-2 following ileo-cecal resection augments putative intestinal stem cell expansion

2009 ◽  
Vol 296 (3) ◽  
pp. G643-G650 ◽  
Author(s):  
Aaron P. Garrison ◽  
Christopher M. Dekaney ◽  
Douglas C. von Allmen ◽  
P. Kay Lund ◽  
Susan J. Henning ◽  
...  
Keyword(s):  
Side Population ◽  
Intestinal Failure ◽  
Serum Levels ◽  
Optimal Timing ◽  
Side Population Cells ◽  
Stem Cell Expansion ◽  
Crypt Fission ◽  
Igf I ◽  
Glucagon Like Peptide ◽  
Mucosal Mass

Expansion of intestinal progenitors and putative stem cells (pISC) occurs early and transiently following ileo-cecal resection (ICR). The mechanism controlling this process is not defined. We hypothesized that glucagon-like peptide-2 (GLP-2) would augment jejunal pISC expansion only when administered to mice immediately after ICR. Since recent reports demonstrated increases in intestinal insulin-like growth factor (IGF)-I following GLP-2 administration, we further hypothesized that increased intestinal IGF-I expression would correlate with pISC expansion following ICR. To assess this, GLP-2 or vehicle was administered to mice either immediately after resection (early) or before tissue harvest 6 wk following ICR (late). Histological analysis quantified proliferation and intestinal morphometrics. Serum levels of GLP-2 were measured by ELISA and jejunal IGF-I mRNA by qRT-PCR. Expansion of jejunal pISC was assessed by fluorescent-activated cell sorting of side population cells, immunohistochemistry for phosphorylated β-catenin at serine 552 (a pISC marker), percent of crypt fission, and total numbers of crypts per jejunal circumference. We found that early but not late GLP-2 treatment after ICR significantly augmented pISC expansion. Increases in jejunal IGF-I mRNA correlated temporally with early pISC expansion and effects of GLP-2. Early GLP-2 increased crypt fission and accelerated adaptive increases in crypt number and intestinal caliber. GLP-2 increased proliferation and intestinal morphometrics in all groups. This study shows that, in mice, GLP-2 promotes jejunal pISC expansion only in the period immediately following ICR. This is associated with increased IGF-I and accelerated adaptive increases in mucosal mass. These data provide clinical rationale relevant to the optimal timing of GLP-2 in patients with intestinal failure.

Sign in / Sign up

Export Citation Format

Share Document